Approved Immune Checkpoint Inhibitors in China: PD-1, PD-L1, CTLA-4 and Bispecific Antibodies
Immune checkpoint inhibitors (ICIs) restore T-cell–mediated antitumor immunity by blocking key regulatory pathways such as PD-1/PD-L1 and CTLA-4, and have become a cornerstone of modern oncology treatment. As one of the world’s most important markets for oncology innovation, China has established a comprehensive development landscape covering both monoclonal antibodies and bispecific antibodies. As of April … Continue reading Approved Immune Checkpoint Inhibitors in China: PD-1, PD-L1, CTLA-4 and Bispecific Antibodies
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed